Bevacizumab is an anti-VEGF monoclonal antibody and is reported to have antitumor activity against HCC, ovarian cancer, renal cell cancer, pancreatic cancer, and soft tissue sarcoma when it is administered alone or in combination with chemotherapy [25]. Here, VEGFA is linked to soft tissue sarcoma.